The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction.
D047228:Angiotensin II Type 1 Receptor Blockers; D000818:Animals; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D015870:Gene Expression; D000077405:Irbesartan; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism; D009206:Myocardium / Q000737:chemistry / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1 / Q000032:analysis; D043783:Receptor, Bradykinin B1 / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D013777:Tetrazoles / Q000627:therapeutic use*
D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; D043783:Receptor, Bradykinin B1; D013777:Tetrazoles; D000077405:Irbesartan